Skeletal muscle and connective tissue recovery is one of the most actively researched areas in peptide science. The ability to reduce delayed-onset muscle soreness (DOMS), accelerate tendon healing, and restore structural integrity after injury has obvious implications for sports science and rehabilitation research. This guide covers the four most researched recovery peptides available in India, their mechanisms, and representative dosing protocols.
For reconstitution of any of the peptides below, use the BAC water reconstitution calculator to prepare your working solution accurately.
BPC-157: The Foundation of Recovery Research
BPC-157 (Body Protection Compound-157) is the starting point for virtually every recovery peptide research programme. It is a synthetic 15-amino acid peptide derived from a gastric juice protein, and it has a uniquely broad mechanistic profile for tissue repair. It upregulates VEGFR2 (vascular endothelial growth factor receptor 2) and EGF receptor, promoting angiogenesis at injury sites. It also directly stimulates fibroblast migration and proliferation, the cellular machinery responsible for laying down new collagen and extracellular matrix.
Of particular note for musculoskeletal research: BPC-157 appears to counter the tendon-weakening effects of corticosteroids and NSAIDs in preclinical models — compounds commonly used in injury management that have well-documented negative effects on long-term tendon integrity. Researchers studying tendon-to-bone healing and ligamentous injuries consistently find BPC-157 among the most reproducible interventions across animal models.
Research dosing: 250–500 mcg/day, subcutaneous or intramuscular injection. Injection proximal to the area of research interest is commonly used. Storage at -20°C lyophilised; 4°C once reconstituted, use within 4 weeks.
TB-500: Systemic Recovery Through Actin Regulation
TB-500 (Thymosin Beta-4) is a naturally occurring 43-amino acid peptide present in virtually all nucleated cells. Its primary recovery mechanism operates through sequestration of G-actin monomers, which regulates actin polymerisation dynamics critical for cell migration. In injury response research, TB-500 administration has been shown to mobilise progenitor cells from bone marrow, direct their migration to damaged tissue, and support angiogenesis through upregulation of metalloproteinases that remodel the extracellular matrix.
Unlike BPC-157, which works best near the injury site, TB-500's systemic distribution via the lymphatic circulation makes it effective for injuries at anatomically difficult locations — joints, tendons with poor local vascularity, and distributed muscle damage from DOMS. This complementary biodistribution makes the BPC-157 + TB-500 stack one of the most rational combinations in recovery research.
Research dosing: 2–2.5 mg twice weekly, subcutaneous injection. Can be paired with BPC-157 in the same recovery protocol.
GHK-Cu: Collagen Synthesis and Tissue Remodelling
GHK-Cu (copper peptide) is a naturally occurring tripeptide-copper complex found in human plasma, urine, and saliva. Its role in tissue repair centres on its ability to activate over 4,000 genes involved in tissue remodelling, collagen synthesis, and wound healing — a breadth of gene regulatory activity unusual for such a small molecule. GHK-Cu upregulates fibronectin production, stimulates glycosaminoglycan synthesis (essential for connective tissue hydration and resilience), and promotes the differentiation of fibroblasts into myofibroblasts that contract and close wound matrices.
For muscle recovery research, GHK-Cu's collagen-stimulating properties are relevant to the connective tissue components of muscle — fascia, epimysium, perimysium — that undergo stress during intense training. Researchers studying age-related muscle composition changes are also interested in GHK-Cu for its anti-fibrotic effects, which may prevent the fibrous replacement of functional muscle tissue seen in sarcopenia models.
Research dosing: 1–2 mg/day, subcutaneous injection or topical application for skin research. Available in the recovery peptides collection.
TB-4 Frag (Ac-SDKP): Targeted Anti-Fibrotic Action
The N-terminal fragment of Thymosin Beta-4, Ac-SDKP (acetyl-serine-aspartate-lysine-proline), represents a specialised research tool for fibrotic processes in muscle and other tissues. While TB-500 provides the broad recovery benefits of full-length Thymosin Beta-4, Ac-SDKP specifically inhibits TGF-beta1-induced fibrosis — the pathway responsible for scar tissue formation in muscle following chronic injury or inflammation. Researchers studying DOMS mechanisms have noted that attenuating the fibrotic response during repeated-bout injury models maintains muscle architecture and functional recovery capacity over longer research periods.
Ac-SDKP also inhibits inflammatory macrophage activation, addressing the inflammatory phase of muscle damage resolution and potentially shortening the window of impaired force production following muscle injury.
Recovery Research Protocol Summary
All four peptides described above are available at Peptide Central at 99% HPLC-verified purity with COA included. Pan-India COD delivery is available for all recovery peptides. Browse the full recovery peptides collection for current stock, pricing, and combination bundles. Prepare each peptide separately using the BAC water calculator for accurate concentration.